Exchange: NASDAQ·Updated 07:40 PM EST

LENZ News

News
all
press releases
LENZ Therapeutics, Inc. (LENZ) Reports Q3 Loss, Misses Revenue Estimates
LENZ Therapeutics, Inc. (LENZ) delivered earnings and revenue surprises of -2.06% and -15.67%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
LENZ Therapeutics, Inc. (LENZ) Reports Q3 Loss, Misses Revenue Estimates
LENZ Therapeutics, Inc. (LENZ) delivered earnings and revenue surprises of -2.06% and -15.67%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
More News
Regeneron (REGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZPR NewswireNEW YORK, Sept. 24, 2026 NEW YORK, Sept. 24, 2026 /PRNewswire...
PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZPR NewswireNEW YORK, Sept. 17, 2026 NEW YORK, Sept. 17, 2026 /PRNewswire...
PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ PR Newswire NEW YORK, Sept. 10, 2026 NEW YORK, Sept. 10, 2026 /PRNewswire...
PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ PR Newswire NEW YORK, Sept. 3, 2026 NEW YORK, Sept. 3, 2026 /PRNewswire...
PR Newswire
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets
LENZ Therapeutics, Inc. (LENZ) delivered earnings and revenue surprises of +15.70% and +148.24%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
CG Oncology, Inc. (CGON) delivered earnings and revenue surprises of -28.57% and -59.02%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks

Advertisement|Remove ads.